Zalicus +43.5% AH; Epirus releases positive BOW015 data

|By:, SA News Editor

A Phase 3 study on the efficacy and safety of Epirus' BOW015 rheumatoid arthritis drug relative to the currently-available Remicade "met its pre-specified statistical endpoint," and found "no meaningful differences observed in safety or immunogenicity."

Results from the open label testing phase, including "one year immunogenicity, one year safety, and long-term responder rates," are expected in Q3.

Epirus merger partner Zalicus (ZLCS) is responding quite well to the news.